Cargando…

Apomorphine Monotherapy for Parkinson’s Disease: A Neglected Option?

Detalles Bibliográficos
Autores principales:	Desjardins, Clément, Nilles, Christelle, Devos, David, Roze, Emmanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Movement Disorder Society 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548076/ https://www.ncbi.nlm.nih.gov/pubmed/37291833 http://dx.doi.org/10.14802/jmd.23057

Ejemplares similares

Apomorphine in Parkinson's Disease—The Questions Raised
por: Dhamija, Rajinder K., et al.
Publicado: (2020)

Looking Beyond the Fog—Apomorphine Demystified
por: LK, Prashanth, et al.
Publicado: (2020)

Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study
por: Meira, Bruna, et al.
Publicado: (2021)

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
por: Agbo, Felix, et al.
Publicado: (2021)

Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson’s disease
por: Hagell, Peter, et al.
Publicado: (2020)

Task Specific Tremor in Parkinson’s Disease Responds to Apomorphine
por: Ondo, William G., et al.
Publicado: (2023)

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease
por: Antonini, Angelo
Publicado: (2009)

Apomorphine
Publicado: (1900)

Apomorphine
Publicado: (1888)

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease
por: Isaacson, Stuart, et al.
Publicado: (2016)

Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations
por: Carbone, Federico, et al.
Publicado: (2019)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Dopamine-transporter levels drive striatal responses to apomorphine in Parkinson's disease
por: Passamonti, Luca, et al.
Publicado: (2013)

Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson's disease
por: Borkar, Nrupa, et al.
Publicado: (2018)

Night‐Time Apomorphine Infusion: Who Are the Best Candidates?
por: Cochen De Cock, Valérie, et al.
Publicado: (2023)

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
por: Gaire, Suman, et al.
Publicado: (2021)

Investigation of apomorphine during sleep in Parkinson’s: Improvement in UPDRS Scores
por: Pieroni, Miguel A.
Publicado: (2019)

Neglected Tropical Diseases in Pakistan: A Story of Neglect
por: KHAN, Aisha, et al.
Publicado: (2020)

A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Apomorphine effects on the hippocampus
por: Arroyo-García, Luis Enrique, et al.
Publicado: (2018)

On the Anæsthetic Action of Apomorphine
Publicado: (1885)

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson's Disease
por: Nishijima, Haruo, et al.
Publicado: (2018)

Is Apomorphine a Safe Emetic?
por: Brown, John
Publicado: (1889)

Some Observations on the Use of Apomorphine
por: Horsley, J. S.
Publicado: (1912)

Practical use of apomorphine infusion in Parkinson’s disease: lessons from the TOLEDO study and clinical experience
por: Henriksen, Tove, et al.
Publicado: (2023)

Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson’s disease: the APOKADO study
por: Zagnoli, Fabien, et al.
Publicado: (2023)

Cost-Effectiveness of Apomorphine Sublingual Film as an “On-Demand” Treatment for “OFF” Episodes in Patients with Parkinson’s Disease
por: Thach, Andrew, et al.
Publicado: (2021)

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
por: Agbo, Felix, et al.
Publicado: (2021)

A deep eutectic-based, self-emulsifying subcutaneous depot system for apomorphine therapy in Parkinson’s disease
por: Kim, Jayoung, et al.
Publicado: (2022)

Continuous subcutaneous apomorphine infusion allowing awake deep brain stimulation in a Parkinson’s disease patient
por: Spagnolo, Francesca, et al.
Publicado: (2021)

Neglected tropical diseases and global burden of disease in China
por: Qian, Men-Bao
Publicado: (2017)

Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?
por: Hauser, Robert A., et al.
Publicado: (2023)

Monotherapy with liraglutide – Points to be focussed
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019)

Apomorphine Hydrochloride in the Treatment of Persistent Hiccough
por: Panda, R. C.
Publicado: (1928)

The Pharmacological Properties and Therapeutic Use of Apomorphine
por: Ribarič, Samo
Publicado: (2012)

Necrotic Ulcers Secondary to Apomorphine Infusion
por: Llamas-Osorio, Yudy, et al.
Publicado: (2021)

Ventricular Bigeminy after Subcutaneous Administration of Apomorphine in a Patient with Refractory Parkinson’s Disease: A Case Report
por: Kaminioti, Anastasia N., et al.
Publicado: (2013)

Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson’s disease: A prospective study of 22 patients
por: Fernández-Pajarín, Gustavo, et al.
Publicado: (2021)

Apomorphine Targets the Pleiotropic Bacterial Regulator Hfq
por: Turbant, Florian, et al.
Publicado: (2021)

Neglecting the Elderly Diabetic?
por: Sinclair, Alan J
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_n26arurmgl9f3jhr8h6t3h075q